Pro­to­cols: No­var­tis CEO is still map­ping out San­doz's fu­ture; But Swiss gi­ant is gung ho on all things dig­i­tal

→ No­var­tis CEO Vas Narasimhan is rais­ing some eye­brows to­day as he dis­cuss­es the fu­ture of San­doz, the phar­ma gi­ant’s big gener­ics unit. “We con­sid­er San­doz an in­te­gral part of No­var­tis, we’re fo­cused on trans­form­ing the busi­ness, mak­ing it an au­tonomous en­ti­ty over the next 18 months that is able to com­pete as an in­de­pen­dent unit with­in No­var­tis,” he told an­a­lysts, ac­cord­ing to a re­port in Reuters. “Af­ter we com­plete all that, then I think we can have fur­ther con­ver­sa­tions about where we want to head from there.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER